Researchers at Johns Hopkins University, Northwestern University, and Amgen Inc. report that Filgrastim, a human growth factor sometimes taken as a supplement to anti-HIV therapy, may actually hinder the effectiveness of the HIV antiretroviral medications, AIDSWeekly reports. Filgrastim, a granulocyte colony stimulating factor, is used to reverse neutropenia in HIV-positive people and AIDS patients suffering from cytomegalovirus infections. But the researchers found that HIV viral loads dropped more slowly among those who add the compound to their anti-HIV drug regimen than those who do not take Filgrastim. The difference was slight but statistically significant, the researchers report. The compound likely interferes with the anti-HIV activity of the medications, and that allows HIV to replicate more easily.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














